A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Completed · Phase 2 · NCT05635708
Conditions: Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $685,268
- U.S. investigators named
- 5
- Sites paid
- 6
- Planned or actual enrollment
- 418
About the trial
- Sponsor
- BeiGene
- Tested
- Tislelizumab (drug), BGB-A445 (drug), LBL-007 (drug), Carboplatin (drug), Cisplatin (drug), pemetrexed (drug), Paclitaxel (drug), Nab paclitaxel (drug), BGB-15025 (drug)
- Dates
- Started 2023-02-10; completion 2026-10-29
- Results posted
- Not yet
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).
From ClinicalTrials.gov, last updated 2026-10-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $685,268 in research payments for this study in 2025 (114 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David Berz, MD, PHD, MPH Hematology & Oncology · Los Angeles, CA
- Justin F. Gainor, MD Medical Oncology · Boston, MA
- Jamie E. Chaft, MD Medical Oncology · New York, NY
- Rachel E. Sanborn, MD Medical Oncology · Portland, OR
- George R. Blumenschein JR., M.D. Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Valkyrie Clinical Trials, Inc $412,040
- Providence Portland Medical Center, OR $119,004
- Memorial Sloan Kettering Cancer Center $73,639
- Ut MD Anderson Cancer Center $42,714
- Dana Farber Mass General Brigham Cancer Care Inc $28,892
- Massachusetts General Hospital, MA $8,979
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.